ACAida Carreño

Aida Carreño

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Aida Carreño has a total of 67 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of the protein corona in RGD-functionalized nanoliposomes delivering enzymatic replacement therapy for Fabry disease

    by Marc Moltó-Abad, Judit Tomsen-Melero, Verónica Villagrasa-Araya, Daniel Marijuan-Pinel, Zamira V. Díaz-Riascos, Francesc Canals, Luna Martín, Guillem Pintos-Morell, Sandra Mancilla, Belén García, et al.

  • Open Access

    Targeted nanoliposomes to improve enzyme replacement therapy of Fabry disease

    by Judit Tomsen-Melero, Marc Moltó-Abad, Josep Merlo-Mas, Zamira V. Díaz-Riascos, Edgar Cristóbal-Lecina, Andreu Soldevila, Thomas Altendorfer-Kroath, Dganit Danino, Inbal Ionita, Jan Skov Pedersen, et al.

    The central nervous system represents a major target tissue for therapeutic approach of numerous lysosomal storage disorders. Fabry disease arises from the lack or dysfunction of the lysosomal alpha-galactosidase A (GLA) enzyme, resulting in substrate accumulation and multisystemic clinical manifestations. Current enzyme replacement therapies (ERTs) face limited effectiveness due to poor enzyme biodistribution in target tissues and inability to reach the brain. We present an innovative drug delivery strategy centered on a peptide-targeted nanoliposomal formulation, designated as nanoGLA, engineered to selectively deliver a recombinant human GLA (rhGLA) to target tissues. In a Fabry mouse model, nanoGLA demonstrated improved efficacy, inducing a notable reduction in Gb3 deposits in contrast to non-nanoformulated GLA, even in the brain, highlighting the potential of the nanoGLA to address both systemic and cerebrovascular manifestations of Fabry disease. The EMA has granted the Orphan Drug Designation to this product, underscoring the potential clinical superiority of nanoGLA over authorized ERTs and encouraging to advance it toward clinical translation.


  • Open Access

    Interlaboratory comparison of endotoxin contamination assessment of nanomaterials

    by Gary Hannon, Bethany J. Heaton, Alexander Plant-Hately, Christopher David, Neill J. Liptrott, Ainhoa Egizabal, Ana Ayerdi-Izquierdo, Noelia Alvarez, Oihane Ibarrola, Andres Arbona Celaya, et al.

    Endotoxin contamination is a significant hurdle to the translation of nanomaterials for biomedical applications.


  • Open Access

    Tuning plasmid DNA amounts for cost-effective transfections of mammalian cells: when less is more

    by Aida Carreño, Rubén Guerrero-Yagüe, Enriqueta Casal, Rosa Mendoza, José Luis Corchero

    Transient gene expression (TGE) in mammalian cells is a well-known approach to the fast expression of recombinant proteins. The human cell line HEK (human embryonic kidney) 293F is widely used in this field, due to its adaptability to grow in suspension to high cell densities in serum-free media, amenability to transfection, and production of recombinant proteins in satisfactory quantities for functional and structural analysis. Amounts of plasmid DNA (pDNA) required in transfections for TGE remain high (usually 1 µg pDNA/mL, or even higher), representing a noticeable proportion of the overall cost. Thus, there is an economic need to reduce amounts of coding pDNA in TGE processes. In this work, amounts of both pDNA and transfecting agent used for TGE in HEK 293F cells have been explored in order to reduce them without compromising (or even improving) the productivity of the process in terms of protein yield. In our hands, minimal polyethyleneimine (PEI) cytotoxicity and optimum protein yields were obtained when transfecting at 0.5 µg pDNA/mL (equal to 0.5 µg pDNA/million cells) and a DNA-to-PEI ratio of 1:3, a trend confirmed for several unrelated recombinant proteins. Thus, carefully tuning pDNA and transfecting agent amounts not only reduces the economic costs but also results in higher recombinant protein yields. These results surely have a direct application and interest for the biopharmaceutical industry, always concerned in increasing productivity while decreasing economic costs. Key points: • Mammalian cells are widely used to produce recombinant proteins in short times. • Tuning DNA and transfecting agent are of great interest to optimize economic costs. • Reducing DNA and transfecting agent amounts result in higher protein yields. Graphical


  • Open Access

    All-in-one biofabrication and loading of recombinant vaults in human cells

    by Fernando Martín, Aida Carreño, Rosa Mendoza, Pablo Caruana, Francisco Rodriguez, Marlon Bravo, Antoni Benito, Neus Ferrer-Miralles, M Virtudes Céspedes, José Luis Corchero

    One of the most promising approaches in the drug delivery field is the use of naturally occurring self-assembling protein nanoparticles, such as virus-like particles, bacterial microcompartments or vault ribonucleoprotein particles as drug delivery systems (DDSs). Among them, eukaryotic vaults show a promising future due to their structural features, in vitro stability and non-immunogenicity. Recombinant vaults are routinely produced in insect cells and purified through several ultracentrifugations, both tedious and time-consuming processes. As an alternative, this work proposes a new approach and protocols for the production of recombinant vaults in human cells by transient gene expression of a His-tagged version of the major vault protein (MVP-H6), the development of new affinity-based purification processes for such recombinant vaults, and the all-in-one biofabrication and encapsulation of a cargo recombinant protein within such vaults by their co-expression in human cells. Protocols proposed here allow the easy and straightforward biofabrication and purification of engineered vaults loaded with virtually any INT-tagged cargo protein, in very short times, paving the way to faster and easier engineering and production of better and more efficient DDS.